Hvilken er prisen på Scilex Holding Company (SCLX)

Prisen på Scilex Holding Company (SCLX) er $5.61

Hva er markedsverdien på Scilex Holding Company (SCLX)

Markedsverdien på Scilex Holding Company (SCLX) er $47.65M

Scilex Holding Company (SCLX) Utbytteavkastning

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

År	Utbytteavkastning	Endre
Ikke nok data for de angitte datoene.

År

Utbytteavkastning

Endre

Ikke nok data for de angitte datoene.

Selskap	Utbytteavkastning	Land
Eli Lilly and Company LLY.US	0.57%	US
Johnson & Johnson JNJ.US	2.01%	US
AbbVie Inc. ABBV.US	2.74%	US
Roche Holding AG RO.SW	2.69%	CH
Merck & Co., Inc. MRK.US	2.47%	US

Selskap

Utbytteavkastning

Land

Eli Lilly and Company

LLY.US

0.57%

Johnson & Johnson

JNJ.US

2.01%

AbbVie Inc.

ABBV.US

2.74%

Roche Holding AG

RO.SW

2.69%

Merck & Co., Inc.

MRK.US

2.47%

Scilex Holding Company

SCLX

Kategori